Additionally, treatment with adavosertib (WEE1 inhibitor, MK-1775) or panobinostat (pan-HDAC inhibitor) exhibited in vitro and in vivo anti-AML efficacy against mtNPM1-expressing AML cell models that were either sensitive or resistant to MI treatment. This evidence concerns the gene HDAC9 and acute myeloid leukemia.